Scientific Program

Day 1

KEYNOTE SPEAKERS
  • Early, non-invasive, rapid detection of various cancers

    Medical Research, Heart Disease Research Foundation
    USA
    Biography

    Yoshiaki Omura received Oncological Residency training at Cancer Institute of Columbia University & Doctor of Science Degree through research on PharmacoElectro-Physiology of Single Cardiac Cells in-vivo and in-vitro from Columbia University. He researched EMF Resonance phenomenon at Graduate Experimental Physics Dept., Columbia University. He published over 270 original research articles, many chapters & 9 books. He is currently Adjunct Prof. of Family & Community Medicine, NY Medical College and Director of Medical Research, Heart Disease Research Foundation of NY. He is the President and Professor of International College of Acupuncture & Electro-Therapeutics, NY. He is the Editor-in-Chief of Acupuncture & Electro-Therapeutics Research, Int’l Journal of Integrative Medicine, (indexed by 17 major int’l Indexing Periodicals). He also serves as an Editor of Integrative Oncology. Formerly, he was also Adjunct Prof. or Visiting Prof. of Universities in USA, France, Italy, Japan, Korea, China, etc.

    Abstract

    Using highly sensitive electromagnetic field (EMF) resonance phenomena between 2 identical molecules with identical weight, we can detect non-invasively any molecules existing inside the body including any cancers without taking blood or biopsies. The method was developed at Graduate Experimental Physics Laboratory of Columbia University. The method was used for detecting Organ Representation Areas (ORA) of specific internal organs. This method is known as an important part of the 4 components of method known as Bi-Digital O-Ring Test (BDORT) for which US Patent was given. The author developed the following different, non-invasive, diagnostic methods: 1a) Using ORA of the face including eyebrows, nose, upper & lower lips by detecting visible changes as well as invisible changes with corresponding biochemical changes. For example, as visible change of malignancy, when specific part of the eyebrow hairs become white in the early stage of the cancer & along the development of cancer the hair disappears. Since the author found different parts of the eyebrows represent specific internal organs, for example if the hair in the lateral end part of the eyebrow becomes white and hair starts disappearing, cancer in the stomach or esophagus can be suspected. In the abnormal areas where there is no hair, if there is a cancer there is always corresponding biochemical changes such as increase of Oncogen CfosAb2 or Integrin ?5?1 & 8-OH-dG which always increases in the presence of malignancy. If the malignancy becomes more aggressive and begins to metastasize, DNA mutilation is always increased and in the abnormal area, 8-OH-dG which is proportional to DNA mutation, is always increased. 1b) Appearance of deep crease. Typical example is deep, horizontal crease about 1.5cm below the lower lip. If the BDORT of the deep crease is abnormal (-)7 or higher (-) value, one can immediately suspect prostate cancer in men and uterus cancer in women. 1c) Abnormal, round projection above the chin often indicates if BDORT is (-)7 or higher (-) value, immediately ovarian cancer can be suspected in women and malignancy of testes or testes-related tissue. 1d) Appearance of discoloration such as brown color at pancreas representation area. 1e) Invisible changes such as abnormal, negative BDORT changes of (-)7 or higher (-) values so the quickest estimate can be made at upper & lower lips as well as nose and breast ORA of the face. For example, in the absence of any visible change, if right upper midline side which represents the stomach has BDORT of (-)7 or higher (-) value, immediately stomach cancer can be suspected. 2) One page of Mouth, Hand, & Foot Writing Form. Completion of it takes 5-10 minutes by each patient. Almost any cancer can be localized from this recording without knowing anything about the patient. 3) From rapidly changing QRS Complex as well as rising part of the T-wave, cancer can often be detected. 4) Abnormal BDORT changes at Thymus Gland ORA. There are 2 additional Thymus gland ORA in the back of each hand in addition to 1 major Thymus gland ORA on the surface of manubrium bone at upper center of the chest. In addition, BDORT of these 3 Thymus gland ORA is average adults is (-)2 but when it becomes less than (-)1 or (+), there is high incidence of malignancy for the corresponding organs. Using these non-invasive, early cancer detection methods, before any standard laboratory test can detect malignancy, we can often detect malignancy long before standard laboratory tests can detect and we can treat cancer in early stage with non-invasive, individualized, safe, effective, economical treatment.

  • Selective and immunomodulating properties of the anticancer proton preparation on basis of Greater Celandine Alkaloids NSC631570

    Ukrainian Anti-Cancer Institute
    Austria
    Biography

    Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Thus, Dr. Nowicky is invited as an Honorable Speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

    Abstract

    One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC631570 repeatedly proven by the results of clinical trials. Until now this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute (the USA)) have shown that the NSC 631570 killed only cancer cells without having damaged the normal cells what confirmed its selective effect.

Cancer Therapy
Chair
Speaker
  • IL-17-MMP7-EMT Axis as Potential Druggable Target in the Prevention and Treatment of Prostate Cancer
    Time: 14:00
    Speaker
    Zongbing You
    Tulane University School of Medicine
    USA
    Biography

    Dr. Zongbing You received his MD at the age of 23 years and PhD at the age of 28 years from West China University of Medical Sciences, Chengdu, China. He is a tenured Associate Professor and Vice Chair for Research as well as Director of the Two-Year Research Master’s Degree Program in the Department of Structural and Cellular Biology at Tulane University School of Medicine, New Orleans, Louisiana, USA. He has published 80 publications and edited a professional book. His research interest is in inflammation and prostate cancer.

    Abstract

    Th17 cells are a subset of T helper cells secreting interleukin-17 (IL-17A and IL-17F). We have systematically investigated the role of IL-17 in prostate cancer. We found that IL-17 receptor C (IL-17RC) expression was up-regulated in human prostatic intraepithelial neoplasia (PIN), hormone naïve prostate cancer, and castration-resistant prostate cancer. Using an Il-17rc;Pten (Phosphatase and tensin homolog) double knockout mouse model, we found that IL-17 promoted development of hormone-naïve and castration-resistant prostate cancer through multiple mechanisms, including: 1) directly stimulating expression of cytokines, chemokines, and growth factors; 2) directly inducing inflammatory cell infiltration; 3) increasing the ratio of immunosuppressive immune cells; 4) increasing angiogenesis; 5) enhancing cellular proliferation; and 6) inhibiting cellular apoptosis. Using an Mmp7;Pten double knockout mouse model, we found that MMP7 promoted prostate adenocarcinoma through induction of epithelial-to-mesenchymal transition (EMT). IL-17 induced MMP7 and EMT in human prostate cancer cell lines, while siRNA knockdown of MMP7 inhibited IL-17-induced EMT. Selective inhibitor of MMP7, inhibitor of Th17 cell differentiation, and anti-IL-17A neutralizing antibodies were able to partially inhibit prostate cancer formation in the Pten knockout mice. These findings demonstrate that IL-17-MMP7-EMT axis plays an important role in prostate cancer development, indicating IL-17-MMP7-EMT axis as a potential target for developing new strategies in the prevention and treatment of prostate cancer

  • Personalized and Precision Oncology through the View of Translational Applications and Innovative Tools to Manage Cancer Progression
    Speaker
    Sergey Suchkov
    Russian Academy of Sciences, Saratov
    Russia
    Biography

    Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Personal: Born 11 January 1957, Astrakhan, Russia. divorced; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, 1985; Doctor Degree, National Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Institute of Medical Enzymology, 1985-87; Senior Research Associate, Koltzov Institute of Developmental Biology, USSR Academy of Sciences, 1987-89; Head of the Lab of Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow, 1989-95; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA, NIH and Laboratory of Immunology, Wills Eye Hospital, Philadelphia, USA, as well as at some of the British Universities on the invitation of the Royal Society for Immunology, 1989; Chairman, Department for Clinical Immunology, Moscow Clinical Research Institute and the Immunologist-in-Chief of the Moscow Regional Ministry of Health, 1995-2004; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal, 1993-1996; Professor in Medicine and Immunology, I.M. Sechenov First Moscow Medical University and Faculty Chairman & Director of the Department of Preventive, Personalized and Translational Medicine, A.I.Evdokimov Moscow State University of Medicine & Dentistry. Honours: Secretary General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; European Association for Predictive, Preventive and Personalized Medicine, Brussels; American Association for Research in Vision and Ophthalmology; International Society for Eye Research; EPMA Journal, Personalized Medicine Universe, Open J.Autoimmunity and American J.Cardiovascular Res. Editorial Boards; All-Union (from 1992 - Russian) Biochemical Society; All-Union (from 1992 - Russian) Immunological Society.

    Abstract

    A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM) to stimulate the development in a variety of clinical disciplines including Personalized and Precision Oncology (PPO). To achieve the implementation of PPO concept into the daily practice, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of cancer-associated bioindicators (biopredictors and biomarkers) of pre-cancer abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact of their decision to use PPO on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the cancer patients and persons-at-risk resulting in improved outcomes whilst securing the healthy state and wellness, reduced adverse events, and more cost effective use of health care resources. Rapidly improving understanding of PPO, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially "actionable." At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. Deciding what therapy options to pursue can also be daunting, especially when tumors harbor more than one potentially actionable aberration. Further, different mutations/variants in a single gene may have different functional consequences, and response to targeted agents may be context dependent. However, early clinical trials with new molecular entities are increasingly conducted in a biomarker-selected fashion, and even when trials are not biomarker-selected, much effort is placed on enrolling patients onto clinical trials where they have the highest probability of response. Implementation of PPO requires a lot before the current model “oncologist-cancer patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPO to elicit the content of the new branch. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration.

  • FXYD3: a promising biomarker for cancer treatment
    Time: 14:30
    Speaker
    Chia-chi Liu
    University of Sydney
    Australia
    Biography

    Dr Chia-chi Liu (BSc, MSc, PhD) is Senior Research Fellow and Molecular Biologist with expertise in oxidative protein chemistry at University of Sydney. She was a Biochemistry Lecturer in Taipei Medical University Taiwan. Dr Liu completed MSc in Cell and Molecular Biology at Taipei Medical University Taiwan, followed by second MSc in Biotechnology, University of New South Wales. She then completed her PhD within the Department of Chemistry and Biomolecular Science, Macquarie University. Dr Liu’s core focus is investigating the relationship between oxidative stress and the sodium pump function. Her research interests include the development of new diagnostic methods for oxidative damage of the pump; the discovery of new drugs for heart disease; and the design of novel therapeutic proteins for cancer treatment.

    Abstract

    Easy access to the Na+-K+ pump in the cell surface membrane and the critical dependence of cell survival on the pump has made it is an attractive therapeutic target in cancer. Use of cardiac glycosides have been explored but has turned out to have limited utility due cardiac toxicity of the drugs. As an alternative we have examined if targeting FXYD proteins that associate closely with the Na+-K+ pump molecular complex might be useful. FXYD3 is of interest because it is markedly over-expressed in several common cancers and we have shown that several FXYD proteins, including FXYD3, are critical for reversal of glutathionylation of the ?1 Na+-K+ pump subunit, an oxidative modification that inhibits pump activity. We hypothesized that FXYD3 protein overexpression protects pump function against inhibition by the high levels of oxidative stress in cancer cells typically encounter and a reduction in FXYD3 expression levels would sensitize cells to chemotherapy and radiotherapy that largely induce cell kill by increasing oxidative stress. In light of the reported treatment resistance of overexpressing FXYD3 cancers, results suggest silencing wild type proteins may greatly strengthen the efficacy of treatments that increase oxidative stress within tumors. Such increases are commonly seen with radiotherapy and chemotherapeutic agents. This ongoing study endeavors to develop amalgamated novel treatments for cancer patients while alleviating side effects associated with traditional therapy; advance diagnosis and improve overall patient well-being.

  • Commentary: How Evolution of Quorum Sensing Must Fit into the Understanding of The Origin, Prevention and Treatment of cancer
    Speaker
    James E. Trosko
    Michigan State University
    USA
    Biography

    james.trosko@hc.msu.edu

    Abstract

    In my article: “Evolution of Microbial Quorum Sensing to Human Global Quorum Sensing: An Insight into How Gap Junctional Intercellular Communication Might Be Linked to the Global Metabolic Disease Crisis” 2, I attempted to integrate how the original single cell organism, living in an hostile environment, acquired genes to deal with an environment with no oxygen and a need to adapt to changing amounts of nutrients for individual life and the reproductive survival of its species. Its metabolic processes required genes that coded for enzymes needed to metabolize glucose, in the absence of oxygen, to produce energy from an inefficient process to make a couple ATP molecules (anaerobic glycolysis). In addition, to meet the demand that as a single cell, it had to acquire genes to be able to communicate with each other concerning the availability of nutrients. Without that ability to communicate with each other about the status of that nutrient pool, each cell would not change its individual need to consume the nutrients at the “normal” rate. It was the primordial means to communicate that emerged, namely the production of a secreted molecule that could be detected by other members of this population when the nutrient levels are being depleted that would signal all of them to slow down their metabolism. The concept of “quorum sensing” was created to depict this process3. If that means of communicating never occurred, the chances of both individual and species survival would be small.

  • Cancer Cured by Bio Electron's Laser Acupuncture
    Speaker
    Nick Kostovic
    Department of Cancer Research Bio Technological Health Centre
    USA
    Biography

    Nick was born on December 6, 1950 in an area now known as region Dalmatia, currently Split Croatia. Nick graduated from Split Gymnasium in 1969 with an Associate of Arts Degree in Humanities and Science. Nick was a US citizen. I have strong Italian ties through my father, Ivo Kostovic who has Italian and Asian origins. He was born on the island of Drvenik-Veli when it was part of region Dalmatia, Italy called Zirona. My mother Bosiljka Rodic Kostovic, with Russian roots, was born in city Omis also originally from Dalmatia region, Italy. Dalmatia was part of Italy for many centuries and currently Dalmatia is located in Croatia Europe.

    Abstract

    New Advanced Technology in Medicine by Bio Electron’s Photons Special circuit I, Nick Kostovic, for the first time in recorded history have eliminated magnetic from regular electromagnetic electricity. I also created the next six steps described below. I did this by developing a proprietary way of reversed current RC to create what is bio electricity. The device I created is called the Kostovic BioTechnological Energizer, K-BTE Medical Laser Device First, my center has successfully developed special current circuit and canceled magnetic from electromagnetic by new discovered RC reverse current. Second, this device extracts bio electron photons from H2O electric fluid by wire and wirelessly. Third, while using the K-BTE device therapist has absolute control of speed/frequency of these released and enriched bio electron photons, by high Voltages /120V, 240V or more/and Micro and Nano Amperes. Today technology can perform only in AC industrial Mili Amperes /it is 1thousand point of 1amperes/ it is to high frequencies, and it is Electric shock therapy and even lethal if performed in higher Voltages from 12 V, to patient with human body resistance to the ground of 1000 Ohm wet. Fourth, bio electrons photons are converted into the strength of Micro / 1million point of 1 Amperes/, or Nano /1billion point of 1 Amperes/ Amperes allowing the bio electricity even with multiple sheaves to softly penetrate into the whole brain, /helping brain to defeat cancer by “burn of” malignant cancer, clean from clots which caused stroke, destroying in the brain number of sick cells which caused different Neurological disorders, with no harm to the healthy cells/spine cord, hearth or any other physical organ with zero harm to the healthy cells. It was never before achieved in the world Medical science. Fifth, in the process of extracting bio electron photons from the electric fluid it can include transference of hundreds of different natural acids as well as amino acids. Each biological agent BA is capable to transfer 3 to 6 different natural and amino acids, by enriched /coated/ bio electron photons in any physical organ including penetration of whole brain for example. World’s science in Medicine is far behind such novel and advanced and most efficient technology in healing and cleaning human organs. Sixth, these enriched bio electrons photons are wirelessly transferred through and olive oil coating on the skin enabling the bio electricity to softly penetrate / bio electron photons always penetrate softly on the skull or skin surface/ deeply and efficiently targeting the specific ailing human tissue. This process is always skillfully directed into the body with the very gentle frequencies of Micro and Nano amperes allowing zero risk of negative consequences.

  • Prognostic association of plasma cell free DNA based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration resistant prostate cancer patients treated with abiraterone acetate
    Speaker
    Manish Kohli
    Mayo Clinic
    USA
    Biography

    He holds an academic rank of Professor and Consultant in Oncology at Mayo Clinic. He has participated extensively in cancer clinical research for the past 15 years. During this time, he has initiated therapeutic trials, recruited several hundred patients for intervention and non-intervention cancer biomarker-based clinical trials and published results of several of these studies. During the course of this research effort, he interacted with multi-disciplinary teams which involved working with geneticists, laboratory scientists, bio-statistical and bio-informatic colleagues, study personnel among others. His early publications were focused on clinical research, mainly in prostate cancer therapeutics. These publications helped advanced therapeutic science in particular with the establishment of docetaxel chemotherapy in castrate resistant prostate cancer in 2004. Subsequently, he built upon these research experiences in developing genomic-based biomarker profiling in advanced prostate/kidney cancer therapeutics as a tool towards developing a precision medicine that is based on cancer’s genetic landscape. In this regard, he initiated the building of prospective clinically annotated bio-repositories, which have uniform processing protocols for obtaining quality research specimens.

    Abstract

    Background. The prognostic significance of plasma cell-free DNA (cfDNA) androgen receptor amplification (ARamp) in metastatic castration resistant prostate cancer (mCRPC) stage is not known. Methods. As part of a prospective study in mCRPC stage, concurrent collection of plasma and circulating tumor cell (CTC) counts was evaluated for determining prognostic value of plasma cfDNA ARamp. Specimen collection was performed twice, after progression on androgen deprivation therapy (baseline) and then repeated after 12 weeks. QuantStudio3D digital PCR Organization Logo Photograph Comment [MK1]: Mayo Clinic institutional policy does not allow us to put their logo here—however I will do so in my presentation . system (dPCR) was used to determine plasma cfDNA AR copy number variations (CNVs) and Cell search assay for enumerating CTC counts. Association of baseline cfDNA ARamp status/CTC counts with overall survival (primary goal) was evaluated using Kaplan–Meier method and log-rank test (p ? 0.05 for significance) and Receiver Operator Curves (ROC) for ARamp status and CTCs ? 5. A multivariate analysis was also performed using Cox regression models that included ARamp, CTC counts, volume of metastatic disease, cfDNA amount, Gleason score and PSA levels. Results. ARamp was detected in 19/70 patients of baseline plasma specimens. At the time of analysis, 28/70 patients had died (median study follow-up 806 days (IQR: 535-966)). ARamp was associated with poor overall survival (2 year OS of 35% vs. 71% in non-ARamp; log-rank p-value= <0.0001). Baseline CTC count ? 5 (vs < 5) was also associated with poor survival (2 year OS of 44% vs 74%); log-rank p=0.001). ROC analysis demonstrated area under the curve (AUC) of 0.66 for ARamp and 0.68 for CTC counts based prognosis (p=0.84 for difference). The best two variables included for multivariable analysis were ARamp and CTC ? 5, however the two factor model was not significantly better than using ARamp alone for predicting survival (HR=5.25; p=0.0002). Conclusions. Plasma cfDNA ARamp has clinical utility as an independent prognostic factor in mCRPC stage.

  • DEAD-BOX RNA HELICASE DP103 ENHANCES YAP SUMOYLATION FOR YAP-TEAD DEPENDENCE AND STATIN SENSITIVITY IN TRIPLE NEGATIVE BREAST CANCER
    Time: 16:00
    Speaker
    Alan Prem Kumar
    Cancer Science Institute of Singapore
    Singapore
    Biography

    Alan Prem Kumar has completed PhD from University of North Texas, USA. He is currently an Assistant Professor at the National University of Singapore. He has over 150 publications that and his publication H-index is 36 and has been serving as an editorial board member of reputed Journals and established several industry collaborations.

    Abstract

    Simvastatin, a lipophilic statin used for lowering cholesterol, inhibits 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the key enzyme of the mevalonate pathway. Studies have shown that cancer cells express deregulated level of HMGCR and statins exert anti-tumoral activities. We first assessed correlation between mevalonate pathway genes and DDX20 (DP103, Gemin-3) in 1325 breast cancer patients and observed a positive correlation between DDX20 and the mevalonate pathway genes. Having this data, we then proceeded to explore the effect of statins on DDX20 expression. We used various in vitro cell lines and in vivo statin clinical trial patients’ specimens, mouse xenograft, mouse intravenous tail injection and Drosophila (wild-type vs Gemin-3 knockdown vs Gemin-3 overexpression flies) models. We show exposure to statin decreases the expression of DDX20. Through a series of add-back experiments, we show that the decrease in DDX20 expression by statins is via the mevalonate pathway and downstream of RhoA. In clinical specimens, we observed breast cancer patients with high baseline DDX20 positively correlates with high baseline YAP-TEAD expression. Having known that SUMOylation of YAP maintains its activity and that DDX20 is a critical enhancer of the SUMOlyation machinery, we showed through a series of experiments that a physical interaction between DDX20 and YAP is crucial for maintaining SUMOylation of YAP; thereby decreasing its ubiquitination and degradation. Interestingly, we also identified for the first time that DDX20 is a direct target of YAP-TEAD complex and that maintenance of DDX20 expression is needed as a positive feedback forming an Achilles heel for sustained YAP-TEAD activity.

  • Therapeutic Targeting of TFF3 Inhibits Oncogenesis in Colorectal Cancer
    Time: 16:30
    Speaker
    Rumei Chen
    National University of Singapore
    Singapore
    Biography

    Chen Rumei received her BSc with academic excellence scholarship from Nan Kai University, China. Upon graduation, she was conferred a full-time PhD research scholarship offered by the Yong Loo Lin School of Medicine in National University of Singapore, Singapore. Her research focus revolves around the profiling of an estrogen-regulated oncogene (TFF3) in CRC and the development of novel therapeutic strategies against it. Meanwhile she has been accredited by Experimental Therapeutics Centre & D3 in Singapore during a course that educate scientists about conducting translational R&D theory and practice. From which, she learnt many practical guidance to translate basic research findings into full-fledged R&D projects. Other than research, Chen has been active in promoting science-related events such as assisting to organize the International Union of Basic and Clinical Pharmacology world conference. She is a member of many international committees, such as European Association for Cancer Research, Pharmacological Society of Singapore.

    Abstract

    Trefoil Factor 3 (TFF3) expression was observed to be upregulated in colorectal cancer (CRC) and correlated with distant metastasis and poor survival outcomes. The present study investigates the functional role of TFF3 and explores the potential of therapeutic inhibition of TFF3 in CRC alone and in combination with conventional chemotherapy. We demonstrated that the forced expression of TFF3 increased cell viability of CRC cells, being attributed to increased cell cycle S-phase entry and decreased apoptosis. Furthermore, the forced expression of TFF3 enhanced the capacity for foci formation and promoted the cancer stem cell-like behaviour of CRC cells. In contrast, the siRNA-mediated depletion of TFF3 decreased the oncogenicity of CRC cells as indicated by the above parameters. Furthermore, AMPC, a novel and selective small molecule inhibitor of TFF3, has been developed in our laboratory and is used to examine the functional implications of TFF3 inhibition in CRC cells. Consistently, AMPC inhibition of TFF3 in CRC cells resulted in reduction of oncogenic properties. Mechanistically, we demonstrate that the TFF3-stimulated oncogenic behavior of CRC cells is dependent on TFF3 activation of the MAPK/ERK pathway. Besides showing efficacy as a single agent, AMPC when used in combination with 5-fluorouracil (5-FU) exhibited a synergistic inhibitory effect, consistent with our observation that TFF3 depletion increased 5-FU sensitivity in CRC cells. In summary, our study highlights the potential of TFF3 as a therapeutic target in CRC and underscores the potential benefits of its pharmacological inhibition in this cancer using AMPC.

Organ Specific Cancers
Chair
Speaker
  • MEMORIAL SYMPTOM ASSESSMENT SCALE (MSAS)
    Speaker
    Inés Llamas Ramos
    University of Salamanca
    Spain
    Abstract

    The MSAS is a multidimensional tool developed to evaluate frequency, severity and distress of common symptoms present in cancer patients. The objective of this project is to show how to adapt and validate the Spanish version of the MSAS. MSAS scale was translated into Spanish and administered to 246 cancer patients aged between 18 and 85. They attended the Day Hospital to receive chemotherapy. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) and Rotterdam Symptom Checklist (RSCL) were used to test criterion validity. The results obtained were that TOTAL MSAS, physical symptom subscale (PHYS), psychological symptom subscale (PSYCH) and global distress index (GDI) reported high internal consistency: 0.891; 0.801; 0.825; 0.813 respectively. Exploratory factor analysis identified two factors structure and confirmatory factor analysis showed good adjustment rates. The emotional functioning subscale of EORTC QLQ-C30 highly correlated with PSYCH (r=-0.868; p<0.001) and GDI (r=-0.810; p<0.001) while social functioning subscale correlated with PSYCH (r=-0.704; p<0.001) and GDI (r=-0.624; p<0.001). The physical symptoms subscale of RSCL correlated with PHYS (r=0.876; p<0.001) and the psychological symptoms subscale with PSYCH (r=0.872; p<0.001). The conclusion of this study was that the Spanish version of MSAS was determined to be a valid and reliable scale in cancer patients.

  • Fertility sparing surgery in treatment of early stages of cervical cancer - new standard of care?
    Speaker
    Aleksandar Stefanovic
    International Federation of Gynecology and Obstetrics(FIGO)
    Serbia
    Biography

    Prof. Aleksandar Stefanovic is the President of Association of gynecologist and obstetricians of Serbia, Montenegro and Republic Srpska also he is theChairman of Clinic of Gyn/Obs, Clinical center of Serbia, Medical Faculty, University of Belgrade, Serbia

    Abstract

    Fertility sparing surgery in treatment of early stages of cervical cancer - new standard of care? Endometrial cancer is the most common cancer of the female genital tract and female patient less than 40 years may account for 3-14% of all endometrial cancers. The promising fact is that in women <45 years, the tumor is mostly low grade disease localized to the endometrium, whereas survival is almost about 100%. An individualized and multidisciplinary approach to each patient is important with intense follow-up, respecting the current recommendations for fertility sparing. Conservative approaches of early-stage endometrial carcinoma includes hormonal therapy in selected group of young patients with endometrial carcinoma age less than 45 years and wishes fertility, showing low grade 1 endometrioid adenocarcinomas (by 2 gyn-oncology pathologists review) is requested limited to the endometrium with MRI excluded myomaterial invasion, without evidence of lymphovascular space involvement or extrauterine disease. Careful and accurate pretreatment assessment of patients considering conservative therapy includes radiologic imaging, hysteroscopy preferably but also contrast-enhanced radiologic imaging-MRI imaging of the ovary (5% of patients with endometrial cancer have synchronous primary tumors). Repeating endometrial biopsies by hysteroscopy every 6 months has been recommended, until there is a complete response or pregnancy. Surgery is recommended if there is no response after 6 months of medication treatment. Hormonal therapy like progestins inhibits the estrogenic effect and suppresses cell proliferation (medroxy progesterone acetate, megestrl acetate), GnRh analogues, but also local gestagens (IUD), oral natural progesterons, aromatase inhibitors, even three step endoscopic (hysteroscopic) resection removal of tumor, surrounding endometrium, myometrium. Fertility after treatment is not guaranteed, even there had been recorded reduced fertility of those treated and there is a significant need of ART (18-60%).

Cancer Management & Prevention
Chair
Speaker
  • Quality of life, mood, social support, and spirituality among breast cancer survivors from different ethnic groups
    Speaker
    Ellen G. Levine
    Walden University
    USA
    Biography

    Ellen G. Levine received her Ph.D. in medical psychology and a M.P.H. in epidemiology from the University of Alabama-Birmingham. She has been a co-PI on 13 psychosocial oncology grants, and 34 publications on different aspects of psychosocial oncology and behavioral medicine. She is currently serving as adjunct faculty at Walden University.

    Abstract

    Th17 cells are a subset of T helper cells secreting interleukin-17 (IL-17A and IL-17F). We have systematically investigated the role of IL-17 in prostate cancer. We found that IL-17 receptor C (IL-17RC) expression was up-regulated in human prostatic intraepithelial neoplasia (PIN), hormone naïve prostate cancer, and castration-resistant prostate cancer. Using an Il-17rc;Pten (Phosphatase and tensin homolog) double knockout mouse model, we found that IL-17 promoted development of hormone-naïve and castration-resistant prostate cancer through multiple mechanisms, including: 1) directly stimulating expression of cytokines, chemokines, and growth factors; 2) directly inducing inflammatory cell infiltration; 3) increasing the ratio of immunosuppressive immune cells; 4) increasing angiogenesis; 5) enhancing cellular proliferation; and 6) inhibiting cellular apoptosis. Using an Mmp7;Pten double knockout mouse model, we found that MMP7 promoted prostate adenocarcinoma through induction of epithelial-to-mesenchymal transition (EMT). IL-17 induced MMP7 and EMT in human prostate cancer cell lines, while siRNA knockdown of MMP7 inhibited IL-17-induced EMT. Selective inhibitor of MMP7, inhibitor of Th17 cell differentiation, and anti-IL-17A neutralizing antibodies were able to partially inhibit prostate cancer formation in the Pten knockout mice. These findings demonstrate that IL-17-MMP7-EMT axis plays an important role in prostate cancer development, indicating IL-17-MMP7-EMT axis as a potential target for developing new strategies in the prevention and treatment of prostate cancer

Day 2

Stem Cells and Oncology
Speaker
  • Anti-proliferative effects of ZFP36L1 and ZFP36L2 on the human colorectal cancer cells
    Speaker
    Yu-Chih Liang
    Taipei Medical University
    Taiwan
    Biography

    Liang YC has completed his PhD at the age of 32 years from National Taiwan University, Taiwan. He is the professor of Taipei Medical University, Taiwan. He has over 100 publications that have been cited over 5000 times, and his publication H-index is 37.

    Abstract

    ZFP36 family members include ZFP36 (also named TTP and TIS11), ZFP36L1 (also called BRF1, ERF1, or TIS11B), and ZFP36L2 (also called BRF2, ERF2, and TIS11D), which belong to CCCH-type zinc finger proteins with two tandem zinc finger (TZF) regions. TTP was found to induce cell senescence by promoting p53 protein expression. However, it is unclear whether ZFP36L1 and ZFP36L2 have antiproliferative activities similar to that of TTP. In this study, a tetracycline-inducible (Tet-On) system was used to induce the expression of ZFP36L1 or ZFP36L2 in T-REx-293 cells by doxycycline (Dox) treatment. Three human colorectal cancer cell lines, HCT116 p53+/+, HCT116 p53-/-, and SW620 (mutated p53) cells, were used to overexpress the wild-type or TZF mutation of ZFP36L1 or ZFP36L2 gene as well as to knockdown the ZFP36L1 or ZFP36L2 gene by lentiviral vectors. When ZFP36L1 or ZFP36L2 was overexpressed, we found that cell proliferation was dramatically inhibited, but did not cause significant cell death. The induction of ZFP36L1 or ZFP36L2 resulted in cell cycle arrest at the G1 phase and an increase in p53 expression. In contrast, levels of cell cycle-related proteins including cyclin B, cyclin D, cyclin A, and p21 decreased in ZFP36L1- or ZFP36L2-overexpressing T-REx-293 cells. Forced expression of ZFP36L1 or ZFP36L2 also inhibited cell proliferation and cyclin D gene expression in these three kinds of cells; however, it increased p53 and p21 expressions only in HCT116 p53+/+ cells. On the other hand, knockdown of ZFP36L1 or ZFP36L2 increased cell proliferation and cyclin D expression, and mutation of the TZF of ZFP36L1 (C135/173R) or ZFP36L2 (C174/212R) caused them to lose their antiproliferative ability, such that they could not inhibit cyclin D expression in these three cell lines. The results suggest that ZFP36L1 and ZFP36L2 play a negative role in cell proliferation of human colorectal cancer cells, and the underlying mechanisms might be mediated through a cyclin D-dependent and p53-independent pathway

  • PD-L1 and PD-1 expression on Circulating Tumor Cells (CTCs) in advanced non-small cell lung cancer (NSCLC) patients treated with nivolumab.
    Speaker
    G.Kallergi
    University of Crete
    Greece
    Biography

    TBA

    Abstract

    Introduction: Circulating tumor cells (CTCs) are considered as a “liquid biopsy” that allows the assessment of tumor changes over time. Tumor cells may escape from the immune system through, among others, the activation of PD-1/PD-L1 axis. Targeting these molecules with monoclonal antibodies has shown encouraging results at many types of cancers including NSCLC. In the current study we investigated the expression of PD-1/PD-L1 molecules on the CTCs isolated from NSCLC patients treated with Nivolumab. Methods: CTCs were isolated based on their size using the ISET platform from 27 patients treated with Nivolumab before treatment, after 1 cycle and after 3 cycles. CTCs were detected after staining with Giemsa and immunofluorescence (IF) double staining using either Cytokeratin (A45-B/B3) (CK7)/PD-1 or Cytokeratin (A45-B/B3)(CK7)//PD-L1 antibodies and analysis with the ARIOL system. Spiking experiments using the NSCLC H460, H1299, HCC827 and SKMES cell lines in normal blood were used to evaluate the detection method. Results: Giemsa evaluation in Nivolumab-treated patients at baseline (25 evaluable samples), after the 1st (9 evaluable samples) and after the 3rd (8 evaluable patients) cycle of treatment showed that CTCs could be detected in 48% (12/25), 33.3% (3/9) and 50% (4/8) of patients, respectively. IF could also reveal the presence of CK-positive cells in 48% (12/25), 22% (2/9) and 75% (6/8) patients, respectively. PD-1 (+) CTCs were detected in 33.3% (4/12) of patients at baseline, in, 0% after the 1 and 16.7% (1/6) of patients after the 3rd cycle whereas PD-L1(+) CTCs in 33.3% (4/12), 0% and 16.7% (1/6),patients, respectively. The expression of PD-1 at baseline was associated with poorer OS (p=0.022) and PFS (p=0.011), while the expression of PD-L1 was associated with shorter PFS (p=0.011). Multivariate analysis revealed that the presence of CK-positive cells is an independent prognostic factor for OS (p=0.028) Conclusion: CTCs from patients with NSCLC express PD-1 and PD-L1 molecules and their expression seems to be associated with the clinical outcome of patients treated with nivolumab.

Organ Specific Cancer
Speaker
  • Pregnancy and breast cancer, repercussions and complications
    Speaker
    Radhouane Achour
    Tunis El Manar University
    Tunisia
    Biography

    Dr.Achour Radhouane is an associate professor at the faculty of medicine of Tunis-Tunisia; He has published many basic and clinical articles in relation to gynecology and obstetrics; His research interests include Rare Diseases in gynecology and prenatal diagnosis. He serves as associate professor, Emergency Department of Gynecology and Obstetrics in maternity and neonatology centre Tunis Tunisia. He also serves as the member of the editorial team for Asian Pacific Journal of Reproduction, the Global Journal of Rare Diseases, Journal of Neonatal Biology, Current pediatric research, Obstetrics and Gynecology: Open access, Pediatrics and Health Research and Member of the Science Advisory Board.

    Abstract

    Breast cancer is common, and is currently considered the first cancer in women . In Tunisia, it accounts for about 30% of all female cancers . The term “pregnancy-associated breast cancer” is used if this cancer is diagnosed during pregnancy and up to one year after giving birth. This association was considered for a long time to be of rapid evolution and unfavorable prognosis. Breast surgery during pregnancy is complicated due to the hypervascularization of the gland during this period. Therefore, it imposes proper hemostasis and lymphostasis. The main effects of radiotherapy during the preimplantation period (from conception to 10 days) are represented by embryonic death and malformation risk during the embryonic phase (days 10-14 up to 8 weeks). When chemotherapy is administered in the first trimester, the rate of malformations is 14% to 19%, and the rate dropped to 1.3% when chemotherapy is introduced in the second or third trimester . The literature reported a 3.8% of fetal malformations in his study, However ; A protocol based on Anthracylins (up to 100 mg/m2 but 50 mg/m2 in most studies) appears to be prescribed without major materno-fetal consequences. EXPERIENCE OF MATERNITY AND NEONATOLOGY CENTER OF TUNIS-TUNISIA We report in this retrospective study a series of 25 patients with pregnancy-associated breast cancer (PABC) recorded over 10 years at the Tunis Maternity and Neonatal Center (TMNC). In conclusion; it seems that the prognosis of breast cancer is not much aggravated by pregnancy itself as by the delay in diagnosis and management. Treatment should be started promptly during pregnancy.

Genetic Mutations & Cancer
Speaker
  • Alternative splicing of extended synaptotagmin-2 as a prognostic biomarker in renal cell carcinoma
    Speaker
    Dan Huang
    The Chinese University of Hong Kong
    China
    Biography

    TBA

    Abstract

    The protein of gene ESYT2 Extended synaptotagmin-2 has been demonstrated to be interacted with the Fibroblast Groth Factor Receptor and activated FGF receptor. It plays an important role in growth factor signaling. However, the expression and function of the transcript variants of this gene is unclear in cancer. In this study, we observed a significant isoform switch of ESYT2 based on the RNA-seq data of the renal cell carcinoma (KIRC) samples downloaded from the TCGA database. Although the expression level of gene ESYT2 is higher in KIRC tumor samples, the expression ratio of the long ESYT2 isoform (ESYT2-L) which includes a cassette exon between exons 13 and 14 to the short isoform (ESYT2-S) is higher in kidney normal samples. The Kaplan-Meier survival curves showed that samples with higher expression ratio of ESYT2-L are associated with better survival (p=2.04e-06). Multivariate Cox proportional hazards regression revealed that the expression ratio of the ESYT2-L could be as an independent prognostic factor for patients with CRC (hazard ratio, 0.037; 95% confidence interval, 0.01-0.125; P=1.24e-07). In addition, the Gene set enrichment analysis (GSEA) revealed that genes correlated with the expression ratio of ESYT2-L are enriched in hallmark of the EMT and invasiveness signature from cancer cell. In conclusion, our findings show that the alternative splicing of ESYT2 could be a potential prognostic biomarker in KIRC and samples with lower expression ratio of the ESYT2-L isoform may be more likely to have the potential to become metastatic.

  • Androgen Receptor: A Potential Therapeutic Target for Glioblastom
    Speaker
    Iris Lavon
    Hadassah Hebrew University Medical Center
    Israel
    Biography

    Iris Lavon is currently the Associate Professor of Neurobiology; She is also the Head of Molecular Neuro-Oncology Laboratory, Neurology Department in Hadassah at Hebrew University Medical Center, Jerusalem, Israel.

    Abstract

    The median survival time of patients with glioblastoma is still poor, partly due to a lack of effective treatment. Following our observation that androgen receptor (AR) is amplified in glioblastomas at the DNA, RNA and protein levels, we have investigated in-vitro and in-vivo the potential of androgen receptor (AR) as a new therapeutic target for glioblastoma. AR gene was amplified in 27% of glioblastoma specimens from men (n=22) and 38.2% of women (n=21). AR-RNA was overexpressed (>2 fold) in 93% (n=30), and AR-protein was induced in 56% of the glioblastomas (n=16). Thirty percent of glioblastomas (n=21) also expressed a constitutively active AR-splice-variant lacking the Ligand-Binding-Domain. Furthermore, AR antagonists, bicalutamide and enzalutamide induced a concentration-dependent death in three glioblastoma cell lines. Enzalutamide given orally to nude mice bearing subcutaneous human glioma xenografts resulted in a 72% reduction in tumor volume (p=0.0027). These results suggest involvement of AR signaling in glioblastoma and raise it as a new potential therapeutic target for this devastating disease.

  • Phase I/IIa trials in GBM patients using a new drug (Cerebraca Wafer) targeting AXL receptor tyrosine kinase
    Speaker
    Shinn-Zong Lin
    Hualien Tzu Chi Hospital
    Taiwan
    Biography

    Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation President, The Buddhist Tzu Chi Bioinnovation Center Charter Fellow of National Academy of Inventor (USA) Fellow of American Association of Advancement of Science (USA) Fellow of American Institute for Medical and Biological Engineering (AIMBE) (USA)

    Abstract

    Malignant brain glioma is a highly invasive disease with a very high death rate. The effective treatment method for this disease is still an unmet medical need. In our previous reports, a pure compound EF-001 showed activities to arrest the growth and initiate apoptosis of malignant brain glioma. To overcome the limitation of the blood-brain barrier, a local-release system with EF-001 incorporated into a biodegradable polyanhydride material, p(CPP-SA), was developed and named “Cerebraca Wafer”. Both the in vitro and the in vivo release kinetics of the Cerebraca Wafers have been characterized. The in situ therapeutic effects of the Cerebraca Wafer on brain gliomas were demonstrated by FGF-SV40 transgenic mice and orthotopic brain tumor F344 rat models. Significant effects on the inhibition of tumor growth and the increase of survival rate by Cerebraca Wafer implantations were observed, with no significant adverse effects on the rodents. Mechanisms involved in the antitumor effect of EF-001, downstream of AXL receptor tyrosine kinase, including the up-regulation of Nurr77 by PKC, the repression of human telomerase reverse transcriptase (hTERT) transcriptional activity via down-regulating Sp1 expression, and the down-regulation of the S-phase kinase-associated protein 2 (Skp2) which resulted in the brain tumor senescence, were also investigated in the study. The toxicity studies and the PIC/s GMP grade Cerebraca Wafer production for clinical trials were accomplished. IND (investigational New Drug) application for the Phase I/IIa clinical trials aiming to determine the safety and the efficacy of Cerebraca Wafer implantation on the recurrent GBM patients have been approved by USFDA and TFDA at 2016. The trial is now being performed at Hualien Tzu-Chi hospital and Tri-Service General hospital, with the first Wafer implantation surgery completed at the end of 2017. The preliminary results for the first three trial patients will be presented and discussed.

Neuro-Oncology and Brain Tumour

Mail us at

General Enquires
oncology@alliedconferences.org
Queries | Sponsorship | Partnering
oncology@alliedconferences.org
USA/Canada
oncology@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

The organizers hold no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, loss, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contact oncology@alliedconferences.org to request a personalized letter of invitation, if not received until one month before the scheduled date of the event.

All the bank charges applicable during refund will be deducted from the account of the participant.

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within the period of one year from the date of rescheduling.

Postponement of event

If due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within the period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to finance@alliedacademies.com. Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of the conferences.

However, Registration cannot be transferred if intimated within 14 days of the respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

 Refund Policy:

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy Orders are available:

  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness of the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

Authorization Policy

Please find the information under More in Homepage bar.

Copyright © 2018-2019 Allied Academies, All Rights Reserved.